Data presented at the AVA Annual Scientific Meeting shows impactful reductions in occlusions, DVT, and phlebitis using materials that mimic the body’s chemistry
BEDFORD, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Access Vascular, Inc. (AVI) , a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today shared initial findings from two new clinical studies that demonstrate a significant reduction in complications when using AVI’s consistently hydrophilic materials for peripherally inserted central catheters (PICC) and midline catheters.
Presented at the Association for Vascular Access (AVA) Annual Scientific Meeting 2021, these early findings highlight the potential for catheters made from advanced biomaterials to reduce patient risks, clinician frustration, and medical expense in vascular access and other applications.
Today, the use of polyurethane-based materials results in catheter-related complication rates for 30 i -34 ii % of insertions because the human body rejects it as a foreign substance. In contrast, AVI’s HydroPICC ® and HydroMID™ catheters made from consistently hydrophilic material are designed to mimic the body’s natural chemistry and reduce both intraluminal and extraluminal complications.
The first retrospective clinical study compared complication rates such as occlusions and replacements in 61 standard PICCs and 60 HydroPICCs, respectively. The study found a statistically significant reduction in complication rates for the HydroPICC group.
The second retrospective study compared complication rates of occlusions, replacements, deep vein thrombosis (DVT), and phlebitis in 100 standard midline catheters and 100 HydroMID catheters. While the data analysis is being finalized, the interim data analysis indicates significantly lower DVT and phlebitis rates in the HydroMID group compared to the standard group. In addition, the total failure rate in the HydroMID group was also significantly lower than in the standard group.
